Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

The Possibility of X-Type Ions With Linear Saturated Non-Reducing Termini Dissociated From Potasiated Saikosaponins.

Rapid communications in mass spectrometry : RCM·2026
Same author

A selective BRG1 inhibitor targeting bromodomain sensitizes hepatocellular carcinoma to chemoradiotherapy by disrupting the DNA damage response.

Chinese medical journal·2026
Same author

Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.

Nature biomedical engineering·2026
Same author

Cr Alloying Enhanced Strength-Ductility Synergy in TiZrNb Alloys at Intermediate Temperature: A Comparative Study with Al and Cu.

Materials (Basel, Switzerland)·2026
Same author

Chromodomain Helicase DNA-Binding Proteins and Spermatogenesis: Current Advances.

Andrology·2026

Related Experiment Video

Updated: Jan 9, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.8K

CDH3 as a Novel Therapeutic Target in Basal-like Double-Negative Prostate Cancer.

Guoqiang Liu, Shiyu Wang, Loan Duong

    Biorxiv : the Preprint Server for Biology
    |December 3, 2025
    PubMed
    Summary

    CDH3 (P-cadherin) drives aggressive basal-like prostate cancer. Therapies targeting CDH3, such as antibody-drug conjugates and CAR T cells, show significant preclinical promise for treating this difficult-to-treat cancer.

    More Related Videos

    Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
    08:37

    Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

    Published on: November 5, 2014

    10.3K
    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    13.7K

    Related Experiment Videos

    Last Updated: Jan 9, 2026

    Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
    07:48

    Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

    Published on: December 26, 2016

    11.8K
    Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
    08:37

    Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

    Published on: November 5, 2014

    10.3K
    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    13.7K

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Therapeutics

    Background:

    • Basal-like prostate cancer is an aggressive subtype lacking effective targeted therapies.
    • CDH3 (P-cadherin) is investigated as a potential therapeutic target in this cancer.
    • Understanding CDH3's role is crucial for developing new treatment strategies.

    Purpose of the Study:

    • To delineate the role of CDH3 in basal-like prostate cancer.
    • To evaluate CDH3-directed therapeutic strategies, including antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T cells.

    Main Methods:

    • Integration of genetically engineered mouse models (GEMMs) and human datasets.
    • Bulk and single-cell transcriptomic analyses to examine CDH3 expression and signaling.
    • In vitro and in vivo functional studies using ADCs and CAR T cells targeting CDH3.

    Main Results:

    • Elevated CDH3 expression and non-canonical WNT signaling in aggressive mouse prostate tumors.
    • CDH3 is significantly upregulated in human basal-like prostate cancer subtypes.
    • CDH3-targeted ADCs and CAR T cells demonstrated potent anti-tumor activity and tumor regression in preclinical models.

    Conclusions:

    • CDH3 is a key marker and functional driver of basal-like prostate cancer.
    • CDH3-targeted therapies (ADCs, CAR T cells) show strong preclinical efficacy.
    • These findings support the development of CDH3-targeted treatments for aggressive prostate cancer.